A human letrozole-resistant breast cancer model used to study aromatase inhibitor resistance, oestrogen signalling, and hormone-directed therapies.
| Inventor | Institute |
|---|---|
| Anne Lykkesfeldt | Danish Cancer Society |
| SKU: | 152550 |
|---|---|
| Product description: | MCF7/LetR-4 is a human breast cancer cell line modelling acquired resistance to letrozole, a third-generation aromatase inhibitor (AI), and was established from parental MCF7/S0.5 cells. Third generation AIs have proven to be effective treatment for oestrogen receptor positive (ER+) breast cancer and as such are recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients. However, a major problem is the development of resistance against Ais such as letrozole. This cell line can be used to study letrozole resistance mechanisms and to discover novel drug targets to develop next-line therapies. |
| Alternate name: | MCF7/LetR-4; LetR-4 |
| Conditional: | No |
| Production details: | Letrozole-resistant cell lines were established from MCF-7/S0.5 cells grown in medium with 10% NCS and 10-7 M testosterone. A culture of MCF-7/S0.5 cells were treated with 10-6 M letrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with letrozole. After ~2-3 months, the isolated colonies gave rise to letrozole-resistant cell lines, which could be grown in letrozole-containing medium with a weekly split ratio of ~1:25. This cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF-7 cell line. |
| Cellosaurus ID: | CVCL_5A20 |
| Parental cell line: | MCF7/S0.5 |
| Disease: | Cancer |
| Related tools: | MCF7/LetR-1 Cell Line ; MCF7/LetR-2 Cell Line ; MCF7/LetR-3 Cell Line Other related cell lines: – LetR-1, LetR-2 and LetR-3 resistant to the non-steroidal AI letrozole – ExeR-1, ExeR-2, ExeR-3 and ExeR-4 resistant to the steroidal AI exemestane – AnaR-1, AnaR-2, AnaR-3 and AnaR-4 resistant to the non-steroidal AI anastrozole |
| Cat. #: | 152550 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Research Fields: | Cancer;Drug development |
| Organism: | Human |
| Tissue: | Breast |
| Growth properties: | Breast cancer cell line resistant to the aromatase inhibitor letrozole. Estrogen receptor positive. |
| Cancer Types In Detail: | Breast cancer |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 1 uM letrozole. |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100 Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755 |
|---|
| Cat. # | Tool Name | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152548 | MCF7/LetR-2 Cell Line |
Key Info
MCF7/LetR-2 Cell Line
|
View Tool | |||||||||||
| 152547 | MCF7/LetR-1 Cell Line |
Key Info
MCF7/LetR-1 Cell Line
|
View Tool | |||||||||||
| 152549 | MCF7/LetR-3 Cell Line |
Key Info
MCF7/LetR-3 Cell Line
|
View Tool | |||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.